Dr. Reddys Laboratories Ltd.

Dainippon Sumitomo Pharma's Sunovion, reportedly has won an U.S appeals court ruling that Dr Reddy's Laboratories' generic version of sleep aid ‘Lunesta’ would breach a patent that expires next year. Further, US Court of Appeals for the Federal Circuit in Washington reportedly opined that there was an error in ruling by the trial Judge who viewed that Dr. Reddy’s version did not infringe the patent. Lunesta generated $136 million in sales during the first quarter in North America and China.

With this development, the company has reached settlements with other companies over the sleep medicine, including one with Teva Pharmaceutical Industries that enable low-cost versions to enter the market before the patent expires.

Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.